Immune checkpoint blockade (ICB) therapy has evolved as a revolutionized therapeutic
modality to eradicate tumor cells by releasing the brake of the antitumor immune response …

Cardiovascular disease and cancer are 2 of the leading causes of death worldwide.
Although improvements in outcomes have been noted for both disease entities, the success …

BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in
these cases for the first and second line is not clear. An international registry was created for …

Background: Despite recent improvements in therapy, the five-year survival rate for patients
with advanced melanoma is poor, mainly due to the development of drug resistance. The …

The development of Immune checkpoint blockade (ICB) therapy and BRAF-and MEK-
targeted therapies has reshaped the survival outcomes of the patients with advanced …

Background: Currently, limited data on targeted therapy and immunotherapy sequencing in
patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy …

Melanoma accounts for a small proportion of skin cancers diagnosed each year, but it has a
high degree of malignancy and rapid progression, resulting in a short survival period for …

The immunopeptidome is constantly monitored by T cells to detect foreign or aberrant HLA
peptides. It is highly dynamic and reflects the current cellular state, enabling the immune …

Background Immune checkpoint inhibitors (ICI) have revolutionized care in oncology with
improved overall survival in several cancer populations. Nivolumab has recently been …

Background Cutaneous melanoma (CM), a kind of skin cancer with a high rate of advanced
mortality, exhibits a wide variety of driver and transmitter gene alterations in the …